Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: A double-blind randomized trial

Journal of Clinical Psychiatry

Volumn 72, Issue 8, 2011, Pages 1086-1094

  Brecht, Stephan ^a   Desaiah, Durisala ^b   Marechal, Elisete S ^c   Santini, Ambra M ^d   Podhorna, Jana ^a   Guelfi, Julien D ^e  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c BOEHRINGER INGELHEIM   (France)

^d Boehringer Ingelheim Italia SpA   (Italy)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; FLUOXETINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FLATULENCE; HAMILTON ANXIETY SCALE; HOSPITAL PATIENT; HUMAN; HYPERHIDROSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT FAILURE; URINE RETENTION; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PSYCHOMETRICS; SUICIDAL IDEATION; THIOPHENES;

EID: 80052495442     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05723blu     Document Type: Article

References (50)

1. Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23):3095-3105. doi:10.101/jama.289.23.3095 PubMed (Pubitemid 37432885)
2. Murray CJL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press; 1996.
3. Beekman AT, Penninx BW, Deeg DJ, et al. The impact of depression on the well-being, disability and use of services in older adults: a longitudinal perspective. Acta Psychiatr Scand. 2002;105(1):20-27. doi:10.1034/j.160-047.202. 1078.x PubMed (Pubitemid 34158064)
4. Herrman H, Patrick DL, Diehr P, et al. Longitudinal investigation of depression outcomes in primary care in six countries: the LIDO study. functional status, health service use and treatment of people with depressive symptoms. Psychol Med. 2002;32(5):889-902. doi:10.1017/S032917020586X PubMed (Pubitemid 34823341)
5. Blair-West GW, Cantor CH, Mellsop GW, et al. Lifetime suicide risk in major depression: sex and age determinants. J Affect Disord. 1999; 55(2-3):171-178. doi:10.1016/S0165-0327(9)04-X PubMed
6. Blair-West GW, Mellsop GW. Major depression: does a gender-based down-based down-rating of suicide risk challenge its diagnostic validity? Aust N Z J Psychiatry. 2001;35(3):322-328. doi:10.1046/j.140-1614.201.0895.x PubMed (Pubitemid 32621856)
7. Nierenberg AA. The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry. 1994;55(suppl A):55-59, discussion 60-61, 98-100. PubMed
8. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol. 2007;22(5):283-291. doi:10.1097/YIC.0b013e3280c56b13 PubMed (Pubitemid 47237547)
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
10. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
11. Montgomery SA, Lecrubier Y; European College of Neuropsychopharmacology. Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. Eur Neuropsychopharmacol. 1999;9(3):259-264. doi:10.1016/S0924-97X(98)048-0 PubMed
12. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry. 1995;56(11):519-525. PubMed
13. Zivkov M, de Jongh GD. Org 3770 vs amitriptyline: a 6-week, randomized, double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol. 1995;10(3):173-180. doi:10.102/hup.47010302
14. Mullin J, Lodge A, Bennie E, et al. A multicentre, double-blind, amitriptyline-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J Psychopharmacol. 1996;10(3):235-240. doi:10.17/02698196010310 (Pubitemid 26280111)
15. Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol. 1997; 17(suppl 1):19S-28S. doi:10.1097/04714-1970401-03 PubMed (Pubitemid 27145752)
16. Kasper S, Zivkov M, Roes KC, et al. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol. 1997;7(2):115-124. doi:10.1016/S0924- 97X(96)0394-X PubMed
17. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry. 1995;56(10):450-458. PubMed
18. Guelfi JD, Ansseau M, Timmerman L, et al; Mirtazapine-Venlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol. 2001;21(4):425-431. doi:10.1097/04714-201080-010 PubMed (Pubitemid 32673032)
19. Shelton RC, Prakash A, Mallinckrodt CH, et al. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract. 2007;61(8):1337-1348. doi:10.1/j.1742-1241. 207.014.x PubMed (Pubitemid 47052368)
20. Pande AC, Sayler ME. Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol. 1993;8(4):267-269. doi:10.1097/04850-1930840-010 PubMed (Pubitemid 23301121)
21. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry. 1999;60(5):326-335. PubMed (Pubitemid 29246899)
22. Clerc GE, Ruimy P, Verdeau-Pallès J; The Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol. 1994;9(3):139-143. PubMed doi:10.1097/04850-194090-01
23. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs. 2001;15(10):765-776. doi:10.2165/023210-201510-03 PubMed (Pubitemid 33065427)
24. Sokero TP, Melartin TK, Rytsälä HJ, et al. Prospective study of risk factors for attempted suicide among patients with DSM-IV major depressive disorder. Br J Psychiatry. 2005;186(4):314-318. doi:10.192/bjp.186.4.314 PubMed (Pubitemid 40524010)
25. Thase ME. Treatment of severe depression. J Clin Psychiatry. 2000;61(suppl 1):17-25. PubMed (Pubitemid 30124146)
26. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63(4):308-315. PubMed
27. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36(6):383-390. doi:10.1016/S02-3956(02)060-2 PubMed (Pubitemid 35254112)
28. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002;63(3):225-231. PubMed (Pubitemid 34407082)
29. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002;36(4):106-132. PubMed
30. Hirschfeld RM, Vornik LA. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J Clin Psychiatry. 2004;65(suppl 4):46-52. PubMed
31. Hunziker ME, Suehs BT, Bettinger TL, et al. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005;27(8):1126-1143. doi:10.1016/j.clinthera.205.08.010 PubMed (Pubitemid 41393910)
32. Girardi P, Pompili M, Innamorati M, et al. Duloxetine in acute major depression: Review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum Psychopharmacol. 2009;24(3):177-190. doi:10.102/hup.105 PubMed
33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
34. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. PubMed
35. Bech P, Allerup P, Gram LF, et al. The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand. 1981;63(3):290-299. doi:10.1/j.160-047.1981.tb0676.x PubMed (Pubitemid 11137960)
36. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health; 1976.
37. Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg Depression Rating Scale corresponding to the definition of remission on the Hamilton Rating Scale for Depression. J Psychiatr Res. 2004;38(6):577-582. doi:10.1016/j.jpsychires.204.03.07 PubMed (Pubitemid 39348889)
38. Faries D, Herrera J, Rayamajhi J, et al. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res. 2000;34(1):3-10. doi:10.1016/S02-3956(9)037-0 PubMed (Pubitemid 30006935)
39. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand. 1975;51(3):161-170. doi:10.1/j.160-047.1975.tb02.x PubMed
40. Bagby RM, Ryder AG, Schuller DR, et al. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry. 2004;161(12):2163-2177. doi:10.176/api.ajp.161.12.2163 PubMed (Pubitemid 39587278)
41. Danish University Antidepressant Group. Citalopram: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Psychopharmacology (Berl). 1986;90(1):131-138. PubMed
42. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol. 1994;8(4):238-249. doi:10.17/02698194080407 (Pubitemid 24373793)
43. Bech P, Tanghøj P, Andersen HF, et al. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl). 2002;163(1):20-25. doi:10.107/s0213-02-147-6 PubMed (Pubitemid 34985308)
44. Mendels J, Johnston R, Mattes J, et al. Efficacy and safety of bid doses of venlafaxine in a dose-response study. Psychopharmacol Bull. 1993;29(2):169-174. PubMed (Pubitemid 23311520)
45. Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998;59(3):116-122. PubMed (Pubitemid 28150857)
46. Danish University Antidepressant Group (DUAG). Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Clin Pharmacol Ther. 1999;66(2):152-165. PubMed
47. Wernicke JF, Dunlop SR, Dornseif BE, et al. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1987;23(1):164-168. PubMed (Pubitemid 17111687)
48. Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry. 1995;38(9):592-602. doi:10.1016/06-323(95)0178-8 PubMed
49. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry. 2003;64(10):1237-1244. PubMed
50. Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry. 2007;68(11):1707-1716. doi:10.408/JCP.v68n10 PubMed (Pubitemid 350247500)